Publications by authors named "Kent Fitzgerald"

Claim this Profile
E
Elevated alpha-synuclein impairs innate immune cell function and provides a potential peripheral biomarker for Parkinson's disease.
Shyra J Gardai, Wenxian Mao, Birgitt Schüle, Michael Babcock, Sue Schoebel, J Kent Fitzgerald

PLoS One· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective and brain-permeable polo-like kinase-2 (Plk-2) inhibitors that reduce α-synuclein phosphorylation in rat brain.
Danielle L Aubele, Roy K Hom, Marc Adler, Robert A Galemmo, Simeon Bowers, Kent Fitzgerald

ChemMedChem· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological inhibition of polo like kinase 2 (PLK2) does not cause chromosomal damage or result in the formation of micronuclei.
Kent Fitzgerald, Marcelle Bergeron, Christopher Willits, Simeon Bowers, Danielle L Aubele

Toxicol Appl Pharmacol· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of highly selective, orally active Polo-like kinase-2 (Plk-2) inhibitors.
Simeon Bowers, Anh P Truong, Michael Ye, Danielle L Aubele, Jennifer M Sealy, Kent Fitzgerald

Bioorg Med Chem Lett· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Laminin-411 is a vascular ligand for MCAM and facilitates TH17 cell entry into the CNS.
Ken Flanagan, Kent Fitzgerald, Jeanne Baker, Karin Regnstrom, Shyra Gardai

PLoS One· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis